Chevy Chase Trust Holdings LLC Has $24.89 Million Stake in Humana Inc. (NYSE:HUM)

Chevy Chase Trust Holdings LLC reduced its position in shares of Humana Inc. (NYSE:HUM) by 2.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,608 shares of the insurance provider’s stock after selling 1,905 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Humana were worth $24,888,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of HUM. International Assets Investment Management LLC increased its holdings in shares of Humana by 32,648.4% in the 4th quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock valued at $61,619,000 after purchasing an additional 134,185 shares during the period. abrdn plc raised its holdings in Humana by 123.9% during the fourth quarter. abrdn plc now owns 192,600 shares of the insurance provider’s stock valued at $88,174,000 after buying an additional 106,586 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Humana by 12.6% during the fourth quarter. Lindbrook Capital LLC now owns 874 shares of the insurance provider’s stock valued at $400,000 after buying an additional 98 shares in the last quarter. Signaturefd LLC raised its holdings in Humana by 1.2% during the fourth quarter. Signaturefd LLC now owns 2,634 shares of the insurance provider’s stock valued at $1,206,000 after buying an additional 30 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Humana by 6.3% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,584 shares of the insurance provider’s stock valued at $5,761,000 after buying an additional 749 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.4 %

HUM stock traded up $1.60 during trading on Wednesday, hitting $358.58. The company had a trading volume of 231,826 shares, compared to its average volume of 1,667,875. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $367.78 and a 200-day moving average price of $346.46. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The stock has a market cap of $43.21 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the previous year, the company posted $8.94 EPS. Humana’s revenue was up 10.4% on a year-over-year basis. As a group, analysts predict that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on HUM shares. Deutsche Bank Aktiengesellschaft raised their target price on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a report on Friday, August 2nd. UBS Group dropped their price objective on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. JPMorgan Chase & Co. lifted their price objective on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research note on Wednesday. TD Cowen lifted their price objective on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, Bank of America lifted their price objective on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research note on Monday, May 20th. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $396.35.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.